BioAtla Investor Presentation Deck

Encouraging Phase 1 results with BA3021 (Ozuriftamab Vedotin) in refractory patients with NSCLC Maximum % Change from Baseline in Sum of Target Lesions bicatla 30% 20% 10% 0% -10% -20% -30% -40% -50% -60% ROR2 + (**TmPS=100) 1.2mg/kg d1,8 I I I I I Suboptimal dose (1.2mg/kg 2Q3W) ROR2 - (**TmPS=0) 3mg/kg d1 Patient experienced tumor shrinkage prior to progression of metastatic bone lesions Response at Variable Dosing ROR2 + (**TmPS=45) 3.3mg/kg d1 NSCLC squamous tumor: 10mm to 0mm on first scan Not Evaluable 1.5mg/kg d1,8 Note: Not Evaluable (Strong, extensive fibroblastic stromal positivity reported) ROR2 + (**TmPS=95) 3.3mg/kg d1 ¶ I ROR2 + (**TmPS=70) 3mg/kg d1 * PR **Suboptimal dose 1.2 mg/kg 2Q3W. Tumor shrinkage occurred prior to progression of metastatic bone lesions. NSCLC squamous tumor 10mm to 0mm on first scan. TmPS = 16%, patient was refractory to four prior lines of therapy including cetuximab and pembrolizumab. ■ Two out of three ROR2+ patients had a confirmed partial response following ozuriftamab vedotin treatment BioAtla| Overview 23

View entire presentation